Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
TRIFERIC (ferric pyrophosphate citrate) is an intravenous iron replacement therapy administered as a solution for patients with iron deficiency anemia, particularly those undergoing hemodialysis. It replenishes iron stores in patients who cannot absorb or tolerate oral iron supplementation. The drug is a small-molecule iron complex designed for direct IV delivery in clinical settings.
Product is in late peak-to-decline transition with formulation patent expiring in 3 years, signaling need for focused retention and lifecycle extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Worked on TRIFERIC at Rockwell Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
TRIFERIC presents a niche career opportunity in specialty pharma focused on hemodialysis and renal disease management; however, the approaching patent expiration in 3 years means this is a retention and defense phase, not growth. Roles available are primarily commercial and medical affairs, with emphasis on customer loyalty and clinical support rather than market expansion.